Author

Number of items: 31.
2004
  • The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. (2004) S. Abel, C. Hundhausen, R. Mentlein, A. Schulte, Theo Berkhout, N. Broadway, D. H. Hartmann, R. Sedlacek, S. Dietrich, B. Muetze, B. Schuster, K.J. Kallen, P. Saftig, S. Rose-John and A. Ludwig
    • 2003
  • CCR2: Characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. (2003) Theo Berkhout, F.E. Blaney, A.M. Bridges, D.G. Cooper, I.T. Forbes, A.D. Gribble, P.H.E. Groot, A. Hardy, R.J. Ife, R. Kaur, K.E. Moores, H. Shillito, J. Willetts and J. Witherington
  • The disintegrin-like metalloproteinase ADAM 10 is involved in coinstitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. (2003) C. Hundhausen, D. Misztela, Theo Berkhout, N. Broadway, P. Saftig, K. Reiss, D. Hartmann, F. Fahrenholz, R. Postina, J. Matthews, K.J. Kallen, S. Rose-John and A. Ludwig
    • 2002
  • Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity. (2002) A. Ludwig, Theo Berkhout, K. Moores, P. Groot and G. Chapman
    • 2001
  • Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists. (2001) Jason Witherington, Vincent Bordas, Dave G. Cooper, Ian T. Forbes, Andrew D. Gribble, Robert J. Ife, Theo Berkhout, Jayneeta Gohil and Pieter H. E. Groot
    • 2000
  • CCR2B receptor antagonists : Conversion of a weak HTS hit to a potent lead compound. (2000) Ian T. Forbes, David G. Cooper, Emma K. Dodds, Deirdre M. B. Hickey, Robert J. Ife, Malcolm Meeson, Martin Stockley, Theo Berkhout, Jayneeta Gohil, Pieter H. E. Groot and Kitty E. Moores
  • Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. (2000) G. A. Chapman, K. E. Moores, D. Harrison, C. A. Campbell, B. R. Stewart, P. J. Strijbos and Theo Berkhout
  • The role of fractalkine in the recruitment of monocytes to the endothelium. (2000) Gayle A. Chapman, Kitty E. Moores, Jayneeta Gohil, Theo Berkhout, Lisa Patel, Paula Green, Colin H. MacPhee and Brian R. Stewart
  • Selective binding of the truncated form of the chemokine CKβ8 (25-99) to CC chemokine receptor 1 (CCR1). (2000) Theo Berkhout, Jayneeta Gohil, Pilar Gonzalez, Charlotte L. Nicols, Kitty E. Moores, Colin H. MacPhee, John R. White and Pieter H. E. Groot
    • 1998
  • Identification of a truncated form of the CC chemokine CKβ-8 demonstrating greatly enhanced biological activity. (1998) Colin H. MacPhee, Edward R. Appelbaum, Kyung Johanson, Kitty E. Moores, Christina S. Imburgia, Jim Fornwald, Theo Berkhout, Mary Brawner, Pieter H. E. Groot, Kevin O'Donnell, Daniel O'Shannessy, Gil Scott and John R. White
  • The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. (1998) N. J. Pearce, J. W. Yates, Theo Berkhout, B. Jackson, D. Tew, H. Boyd, P. Camilleri, P. Sweeney, Andrew D. Gribble, A. Shaw and P. H. E. Groot
    • 1997
  • SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis. (1997) Theo Berkhout, Helen M. Simon, Brian Jackson, John Yates, Nigel Pearce, Pieter H E Groot, Craig Bentzen, Eric Niesor, William D. Kerns and Keith E. Suckling
  • Cloning, in vitro expression, and functional characterization of a novel human CC chemokine of the monocyte chemotactic protein (MCP) family (MCP-4) that binds and signals through the CC chemokine receptor 2B. (1997) Theo Berkhout, Henry M. Sarau, Kitty E. Moores, John R. White, Nabil Elshourbagy, Edward Appelbaum, Theresa J. Reape, Mary Brawner, Jayneeta Makwana, James J. Foley, Dulcie B. Schmidt, Christine Imburgia, Dean McNulty, Jane Matthews, Kevin O'Donnell, Daniel O'Shannessy, Miller Scott, Pieter H E Groot and Colin H. Macphee
  • Induction of cytochrome P4503A by the antiglucocorticoid mifepristone and a novel hypocholesterolaemic drug. (1997) J. Andrew Williams, Richard J. Chenery, Theo Berkhout and Gabrielle M. Hawksworth
    • 1996
  • The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. (1996) Theo Berkhout, Helen M. Simon, Dilip D. Patel, Craig Bentzen, Eric Niesor, Brian Jackson and Keith E. Suckling
    • 1995
  • Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes. (1995) C. R. Albrightson, P. J. Bugelski, Theo Berkhout, B. Jackson, William D. Kerns, A.J. Organ and A. M. Badger
    • 1994
  • SKF 99085 a novel hypocholesterolemic agent with multiple anti-atherosclerotic properties, suppresses HMG-CoA reductase and induces LDL receptor activity by a novel mechanism. (1994) Theo Berkhout, H. Simon, Eric Niesor, Craig Bentzen and Keith E. Suckling
    • 1992
  • The effect of (-)-hydroxycitrate and mevinolin on the activity of the low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase in the human hepatoma Hep G2. (1992) Theo Berkhout, P.H.E. Groot, Louis M. Havekes and N. J. Pearce
    • 1991
  • Effects of a novel lanosterol 14α-demethylase inhibitor on the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in Hep G2 cells. (1991) R. J. Mayer, J. L. Adams, M. J. Bossard and Theo Berkhout
    • 1990
  • The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2. (1990) Theo Berkhout, Louis M. Havekes, N. J. Pearce and P.H.E. Groot
    • 1988
  • Fluorescence studies on the mechanism of action of the cholesteryl ester transfer protein (CETP) in human plasma. (1988) Theo Berkhout
    • 1987
  • Preferential lipid association and mode of penetration of apocytochrome c in mixed model membranes as monitored by tryptophanyl fluorescence quenching using brominated phospholipids. (1987) Theo Berkhout, A. Rietveld and Ben de Kruijff
    • 1986
  • Preferential association of apocytochrome c with negatively charged phospholipids in mixed model membranes. (1986) A. Rietveld, Theo Berkhout, A. Roenhorst, D. Marsh and Ben de Kruijff
    • 1985
  • The lipid binding site of the phosphatidylcholine transfer protein from bovine liver. (1985) D. van Loon, Theo Berkhout, R. A. Demel and K. W. A. Wirtz
  • Coupling of photoactivatable glycolipid probes to apolipoproteins A-I and A-II in human high density lipoproteins 2 and 3. (1985) Theo Berkhout, P. H. Groot, R. van Belzen and K. W. Wirtz
    • 1984
  • Identification of membrane proteins of human blood platelets with a hydrophobic photolabel. (1984) Theo Berkhout, M. E. Schiphorst, K. W. Wirtz and J. J. Sixma
  • Regulation of the activity of phosphatidylcholine transfer protein by vesicle phosphatidic-acid and membrane curvature : a fluorescence study using 2-parinaroylphosphatidylcholine. (1984) Theo Berkhout, C. Vandenbergh, H. Mos, B. Dekruijff and K.W.A. Wirtz
  • Labeling of phospholipids in vesicles and human-erythrocytes by photoactivable fatty-acid derivatives. (1984) Theo Berkhout, A. Vanamerongen and K.W.A. Wirtz
  • Static and time-resolved fluorescence studies of fluorescent phosphatidylcholine bound to the phosphatidylcholine transfer protein of bovine liver. (1984) Theo Berkhout, A.J.W.G. Visser and K.W.A. Wirtz
    • 1983
  • Identification of the lipid-binding site of phosphatidylcholine-transfer protein with phosphatidylcholine analogs containing photoactivable carbene precursors. (1983) J. Westerman, K.W.A. Wirtz, Theo Berkhout, L.L.M. Vandeenen, R. Radhakrishnan and H.G. Khorana
    • 1979
  • Analysis of histones from the yeast Saccharomyces carlsbergensis. (1979) A. Pastink, Theo Berkhout, W.H. Mager and R.J. Planta